Introduction
Perinatal human immunodeficiency virus (HIV) transmission remains a significant challenge in obstetric care. In 1994, the US Public Health Service published guidelines regarding voluntary HIV testing in pregnancy and the treatment of HIV-positive pregnant women. 1, 2 Receiving perinatal zidovudine treatment reduced vertical transmission up to 50% in HIV-positive pregnant women. 3, 4 Since the implementation of these recommendations, the rate of vertical HIV transmission has decreased, but approximately 280-370 perinatal HIV transmissions occurred in the United States in 2001; 138 were reported in 2004. 5, 6 Often, patients do not know their HIV status owing to lack of or late prenatal care, thus denying mothers and infants the opportunity for intrapartum and immediate postpartum HIV treatment.
The Mother-Infant Rapid Intervention At Delivery (MIRIAD) study showed that rapid HIV testing in patients with no or late prenatal care delivered accurate and timely results and allowed HIV-positive patients prompt access to intrapartum and neonatal antiretroviral prophylaxis. 7 The MIRIAD trial found a positive predictive value (PPV) of 76% for the HIV ELISA test versus 90% for the OraQuick rapid HIV test. 7 Available HIV tests contain antigens common to HIV and test for the presence of antibodies to these antigens in the blood or saliva of individuals. The Abbott HIV1/HIV standard ELISA (Abbott HIV-1/HIV-2 EIA, Abbott Laboratories, Abbott Park, IL, USA) contains the p24 core antigen in addition to the envelope proteins gp41, gp120 and gp36; the OraQuick rapid test (Ora-Sure Technologies, Bethlehem, PA, USA) contains the envelope antigens gp41 and gp36. Detection of p24 antigen is the most common reason for false positive western blots in individuals who are not infected with HIV, including pregnant women (B Branson, personal communication,, CDC). According to the Centers for Disease Control and Prevention (CDC), the theoretical PPV of OraQuick in a population with a 0.5% prevalence is in the range of 75-100%. 3, 7 This suggests that the rapid test may be more suited for our population. In this study, we hypothesized that the OraQuick rapid HIV test has a lower false positive rate than the ELISA test (Abbott HIV-1/HIV-2 EIA) in a predominantly Hispanic pregnant patient population. Pregnant patients, regardless of gestational age or pregnancy outcome, were included in the data analysis. Using an electronic charting system, charts were reviewed to obtain age, race and marital status.
Methods
Statistical analysis was carried out using SAS 9.1 (SAS Institute, Cary, NC, USA). Data frequency and PPVs were calculated.
Results
A total of 953 blood samples were collected and evaluated using the HIV ELISA and OraQuick rapid HIV tests. A total of 43 samples were excluded from the data analysis. Eight patients were excluded because of incorrectly recorded medical record numbers, and 35 patients were found to be either male or not pregnant. A total of 910 patients were included in the final data analysis.
Demographic characteristics of this population are shown in Table 1 . All patients were pregnant. The mean age was 26.9 years with a range of 13-44. The majority of the patients were Hispanic (88.9%) and married (66.7%). Test results are summarized in Table 2 . Table 3 outlines the accuracy and PPV of the HIV ELISA test versus the OraQuick rapid HIV test. Fourteen (1.5%) patients were found to have a positive HIV ELISA test, but only 5 (35.7%) of these 14 patients were truly positive for the disease based on the confirmatory western blot assay. The five patients with true positive ELISAs were also found to have positive OraQuick rapid HIV test results. No patient had a false positive test result using the rapid HIV screening test. The PPV for the ELISA test was 35.7%, whereas the OraQuick rapid test had a PPV of 100%. With the exception of one patient who was African-American, all cases of false positives were Hispanic. Although the observed PPVs were clearly different, we aimed to examine their statistical difference. Despite availability of methods to compare sensitivity and specificity of tests, statistical methods to compare predictive values for paired studies have only recently become available. 8 Using the algorithm from this method, comparisons of PPV are performed by obtaining the relative PPV (rPPV) and the corresponding CI. In this study, the rPPV ¼ 2.4 with 90% CI of (1.01, 2.44). The bounded limit does not include one, thus providing evidence for superiority of OraQuick in this population. Here we justify the use of a 90% CI as opposed to conventional 95%, because of the relatively small prevalence of the disease in our population. It should be noted that the 95% limit was not statistically significant.
Discussion
Accurate and rapid diagnosis of HIV is imperative in order to provide appropriate intrapartum treatment to the patient and neonate. Studies have shown a 10% transmission rate when zidovudine prophylaxis is started intrapartum and continued for the first 48 h of life. 9 Current HIV ELISA screening tests require a 12-to 24-h processing time, and results do not return until the postpartum period. In order to begin neonatal treatment promptly, patients often receive positive ELISA results before the confirmatory western blot results. In this study, we found that the PPV for the ELISA test to be low (35%) in a predominantly Hispanic population. However, the OraQuick rapid HIV test had a PPV of 100%, indicating that this screening modality may be more appropriate in this population. Several factors have been implicated to predispose patients to false positive HIV ELISA tests. PPV is prevalence-dependent, and therefore, it is possible that a test may not be as accurate in populations with low prevalence of disease, for example, Hispanics. Consequently, as screening is extended to low-risk populations, statistically the chance of having a false positive test increases. However, if our finding of false positives was because of low prevalence, one would expect both tests used to get similar false positive rates. Alloantibodies (antibodies to foreign tissue from a member of the same species) may cause false positives in cases of pregnancy, transplantation and blood transfusion; false positive tests have also been noted in autoimmune disease. 10 The rapid tests may also produce false positives, which have been associated with multiparity, autoimmune disease, hepatitis A and B, and Epstein-Barr virus.
11 Therefore, the ELISA test, which is highly specific and sensitive in the non-pregnant patient, may yield more false positive results in the pregnant population. A genetic component may also contribute to differences within an ethnic group.
Further studies are necessary before the implementation of the OraQuick rapid HIV test as the HIV screening tool for all patients who present in labor. A larger, multicenter study is needed to determine the generalization of these results. In addition, a complete cost-benefit analysis must be examined. One model that evaluates the costs of treating those with false positive ELISAs suggests that per HIV negative child, the implementation of OraQuick rapid testing costs $98 versus $491 for ELISA testing. 12 Another area of future research would be the use of two sequential rapid tests, such as OraQuick followed by a Multispot confirmatory test, as an alternative to using the ELISA and western blot in order to receive faster but accurate results.
Several study limitations should be considered. First, we relied on laboratory staff to identify blood samples of pregnant patients sent from HCHD facilities. Study eligible blood samples were not saved and screened. Second, our study did not evaluate a significant number of non-Hispanic patients, and our results may not translate to other institutions. Finally, our comparison of PPVs was based on the 90% confidence limits, as opposed to the conventional 95%. Nonetheless, it must be noted that the values of 35.7 and 100% are clearly different, and this difference is clinically relevant.
Current CDC and American College of Obstetricians and Gynecologists recommendations favor HIV testing early and in the third trimester, which allows time to follow-up on false positive ELISAs before delivery. However, some patients will deliver before the third trimester test is done or not have prenatal care, and in those cases rapid testing in labor and delivery (L&D) becomes crucial. Also, some states, such as Texas, have mandated testing early in pregnancy and in L&D. Until such laws are changed, rapid testing in L&D provides more timely reporting of HIV status than ELISA.
Often, the ELISA assay and confirmatory western blot results return after the patient has delivered, missing the window of opportunity to provide intrapartum perinatal zidovudine prophylaxis if necessary. In addition, the result occasionally returns as a false positive and causes needless stress and emotional turmoil for a new mother, as well as unnecessary treatment of the newborn with antiretroviral medications. This study shows that the rapid HIV test has a much lower false positive rate than the ELISA assay in a pregnant patient population that is predominantly low socioeconomic Hispanic. With a faster turnaround time and higher accuracy, the rapid HIV test may soon become the new standard of care for HIV testing on L&D units.
